Oxytocin in neurodevelopmental disorders: Autism spectrum disorder and Prader-Willi syndrome

Pharmacol Ther. 2024 Dec:264:108734. doi: 10.1016/j.pharmthera.2024.108734. Epub 2024 Oct 23.

Abstract

This manuscript reviews recent work on oxytocin and its use in neurodevelopmental disorders including spectrum disorder (ASD) and Prader-Willi syndrome (PWS). Oxytocin is involved in social recognition, bonding, maternal behaviors, anxiety, food motivation, and hyperphagia. While the pathophysiology of ASD and PWS involve abnormalities in the oxytocin system, clinical trials have shown discrepant results in the effectiveness of oxytocin as a treatment for core symptoms associated with these disorders. In this review, we outline oxytocin's clinical pharmacology, safety considerations, and results in recent clinical trials. We propose that oxytocin may be most beneficial in these populations if dosed in a dynamic regimen (PRN) and paired with social interventions.

Keywords: Autism spectrum disorder; Clinical trials; Oxytocin; Prader-Willi syndrome.

Publication types

  • Review

MeSH terms

  • Animals
  • Autism Spectrum Disorder* / drug therapy
  • Autism Spectrum Disorder* / physiopathology
  • Humans
  • Oxytocin* / pharmacology
  • Oxytocin* / therapeutic use
  • Prader-Willi Syndrome* / drug therapy
  • Prader-Willi Syndrome* / physiopathology

Substances

  • Oxytocin